The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update

BACKGROUND: The 2017 Alzheimer’s disease (AD) Strategic Biomarker Roadmap (SBR) structured the validation of AD diagnostic biomarkers into 5 phases, systematically assessing analytical validity (Phases 1–2), clinical validity (Phases 3–4), and clinical utility (Phase 5) through primary and secondary...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccardi, Marina, Dodich, Alessandra, Albanese, Emiliano, Gayet-Ageron, Angèle, Festari, Cristina, Ashton, Nicholas J., Bischof, Gérard N., Chiotis, Konstantinos, Leuzy, Antoine, Wolters, Emma E., Walter, Martin A., Rabinovici, Gil D., Carrillo, Maria, Drzezga, Alexander, Hansson, Oskar, Nordberg, Agneta, Ossenkoppele, Rik, Villemagne, Victor L., Winblad, Bengt, Frisoni, Giovanni B., Garibotto, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175304/
https://www.ncbi.nlm.nih.gov/pubmed/33688996
http://dx.doi.org/10.1007/s00259-020-05120-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175304/
https://www.ncbi.nlm.nih.gov/pubmed/33688996
http://dx.doi.org/10.1007/s00259-020-05120-2

Ejemplares similares